A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis | MicrobiomeTrials
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
CompletedPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-11-29Est. Completion: 2026-08-27
Enrollment target: 108 participants
Locations
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
Tayside Medical Science Centre, Ninewells Hospital & Medical School, Dundee, United Kingdom
NHS Lothian, Edinburgh, United Kingdom
Glasgow Royal Infirmary, Glasgow, United Kingdom
Royal Bromptom Hospital (NHS Guy's and Thomas'), London, United Kingdom
Manchester University NHS Foundation Trust, Manchester, United Kingdom
Medicines Evaluation Unit (MEU), Manchester, United Kingdom
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Other microbiome trials you might be interested in